{"Ab_R": "The paper does not provide a specific description of \"Ab_R\" species, but it discusses therapeutic monoclonal antibodies targeting IL-6 signaling in Crohn's disease, particularly mentioning tocilizumab (anti-IL-6R\u03b1 antibody) and its pharmacological effects in the context of immune regulation and inflammatory responses. The study focuses on multiscale modeling of IL-6 signaling pathways rather than detailing a specific species labeled as \"Ab_R.\"", "Ab_sR_IL6{gut}": "The description of Ab_sR_IL6{gut} species is not explicitly provided in the text you have shared. Please refer to the specific sections of the original paper that detail species descriptions to find the information needed.", "Ab_sR_IL6{liver}": "Ab_sR_IL6{liver} refers to the soluble IL-6 receptor (sIL-6R\u03b1) in the liver, which is implicated in the IL-6 signaling pathway. The liver's involvement is critical due to its role in the upregulation of acute-phase proteins associated with inflammatory conditions like Crohn\u2019s disease. In the context of the multiscale model of IL-6\u2013mediated immune regulation in Crohn's disease, the liver compartment is designed to exchange soluble components with the gastrointestinal tract through blood circulation, therefore emphasizing the interconnectedness of these organs in the pathological process influenced by IL-6 signaling.", "Ab_sR_IL6{serum}": "Ab_sR_IL6{serum} is a monoclonal antibody that targets the interleukin-6 receptor (IL-6R\u03b1), functioning to inhibit IL-6 signaling pathways involved in the inflammatory processes underlying diseases such as Crohn's disease.", "Ab_sR{gut}": "Ab_sR{gut} is a species representing the soluble interleukin-6 receptor (sIL-6R) in the gastrointestinal tract, which is involved in IL-6 mediated signaling and immune regulation in Crohn's disease.", "Ab_sR{liver}": "**Ab_sR{liver}**: The liver compartment models the role of the liver in upregulating acute-phase proteins associated with Crohn\u2019s disease, such as C-reactive protein (CRP). It is linked to the IL-6 signaling module and represents a communication channel through which the liver can respond to and modulate the effects of IL-6-mediated signaling in the gastrointestinal (GI) tract. The liver is included in the multiscale model to account for its significant impact on systemic inflammatory responses in Crohn\u2019s disease.", "Ab_sR{serum}": "The description of Ab_sR{serum} species is not explicitly provided in the text you shared.", "Ab{gut}": "The paper does not appear to provide any specific description of the Ab{gut} species. The focus of the study is on the development of a multiscale systems model of interleukin-6\u2013mediated immune regulation in Crohn\u2019s disease rather than detailing specific species or biological entities.", "Ab{liver}": "The description of Ab{liver} species is as follows:\n\n\"The second compartment models the liver, which was included for its prominent role in the upregulation of acute-phase proteins associated with Crohn\u2019s disease, such as CRP.\"", "Ab{peripheral}": "The description of Ab{peripheral} species is not explicitly stated in the provided text. Consequently, I cannot extract a specific description for \"Ab{peripheral}\" species from this paper.", "Ab{serum}": "Ab{serum} species refers to the concentration of therapeutic monoclonal antibodies measured in the serum. In the context of the study, it is used to describe the pharmacokinetic profiles of anti\u2013IL-6 or anti\u2013IL-6R\u03b1 antibodies, indicating their concentrations over time in the bloodstream as part of evaluating their effects on biomarkers such as serum C-reactive protein (CRP) in patients with Crohn's disease.", "CRP (% of baseline)": "CRP (% of baseline) for Crohn\u2019s disease patients showed a transient reduction in serum levels following treatment with anti\u2013IL-6R\u03b1 antibody, returning to baseline levels by the end of each dosing cycle in the 4-week intravenous administration schedule. The model demonstrated a sustained reduction in serum CRP levels under the 2-week intravenous dosing schedule, although it underestimated the reduction compared to clinical data.", "CRP Suppression (%)": "The description of CRP Suppression (%) for different species is not explicitly listed in the provided text. Please let me know if there is another part of the document or specific information you would like to extract.", "CRPExtracellular": "CRPExtracellular species: C-reactive protein (CRP) is an acute-phase protein that is produced by the liver and is involved in the immune response. It is upregulated in inflammatory conditions, including Crohn's disease, where it can serve as a biomarker for disease activity. In the context of the model, CRP is linked to IL-6 signaling and is produced in response to IL-6 activity, contributing to the inflammatory process associated with the disease.", "CRP{liver}": "CRP (C-reactive protein) is an acute-phase protein whose serum concentrations are reported to increase in patients with Crohn's disease. The production and regulation of CRP are influenced by interleukin-6 (IL-6) signaling. In Crohn's disease, enhanced IL-6 signaling results in elevated levels of CRP, which can serve as a biomarker for inflammation and disease activity.", "CRP{serum}": "**CRP (C-reactive protein) in serum: Serum concentrations of CRP are reported to be significantly elevated in patients with Crohn\u2019s disease, with levels around 7 mg/l compared to 1 mg/l in healthy subjects. This increase is thought to be driven by elevated interleukin-6 (IL-6) levels and is associated with the inflammatory response in the disease.**", "geneProduct": "The species involved in the gene product descriptions in this paper pertain to humans (Homo sapiens).", "gp130{gut}": "gp130 is a coreceptor that plays a crucial role in interleukin-6 (IL-6) signaling. It is almost ubiquitously expressed and can form a heterotrimeric complex with membrane-bound IL-6 and IL-6 receptor (IL-6R\u03b1) or the soluble IL-6 receptor (sIL-6R\u03b1). This complex, when dimerized, activates downstream signaling pathways involving Janus kinase (Jak) family proteins and signal transducer and activator of transcription 3 (STAT3). Additionally, gp130 can exist in a soluble form (sgp130), which acts as a natural inhibitor of IL-6 trans-signaling by sequestering the IL-6/sIL-6R\u03b1 complex.", "gp130{liver}": "The paper does not explicitly provide a distinct description under \"gp130{liver} species.\" It focuses on the multiscale model of IL-6\u2013mediated immune regulation and discusses the role of gp130 within the context of IL-6 signaling pathways and Crohn's disease. It mentions that gp130 is a coreceptor involved in the formation of the hexameric IL-6 receptor complex and that it is almost ubiquitously expressed, including in the liver. There is discussion about the soluble form of gp130 (sgp130) acting as a natural inhibitor of trans-signaling but no specific isolated description labeled \"gp130{liver} species.\"", "IL6{gut}": "IL6{gut} refers to interleukin-6 signaling occurring within the gastrointestinal (GI) tract, which plays a significant role in Crohn's disease. This signaling pathway involves both classical and trans-signaling mechanisms, contributing to the proinflammatory environment in the mucosal layer. In the context of Crohn's disease, IL-6 increases T-cell survival and apoptosis resistance, with levels detected in both intestinal mucosa and serum. This signaling is linked to the regulation of various immune responses and acute-phase protein expression, making it a crucial target for therapeutic strategies.", "IL6{liver}": "IL6{liver} is included in a multiscale model of IL-6-mediated immune regulation in Crohn's disease, which describes the role of IL-6 signaling in the liver, particularly its involvement in the upregulation of acute-phase proteins such as C-reactive protein (CRP). The liver compartment models the dynamics of IL-6 signaling in relation to the disease pathology and pharmacological interventions, allowing for the study of drug effects on systemic markers associated with Crohn\u2019s disease.", "IL6{serum}": "Serum IL-6 is a pro-inflammatory cytokine that is increased in intestinal mucosa and peripheral blood in Crohn's disease. It signals through both classical and trans-signaling pathways, activating the gp130 co-receptor and leading to the phosphorylation of STAT3, contributing to T-cell survival and apoptosis resistance. The serum concentration of IL-6 is thought to drive increases in other biomarkers like C-reactive protein (CRP) and soluble IL-6 receptor (sIL-6R) in Crohn's disease patients.", "pSTAT3{gut}": "pSTAT3 in the gut (pSTAT3{gut}) is measured in arbitrary units (au) and exhibits a fold change from healthy subjects to Crohn's disease patients, where levels increase from 1 au in healthy subjects to 3 au in Crohn's disease patients.", "pSTAT3{liver}": "pSTAT3{liver} is a phosphorylated form of signal transducer and activator of transcription 3 (STAT3) located in the liver. It is involved in the IL-6 signaling pathway, contributing to the modulation of gene expression and biological responses in the context of inflammatory processes, such as those observed in Crohn's disease. In Crohn's disease patients, increased levels of pSTAT3 have been noted in colon biopsies, potentially driven by elevated IL-6 concentrations and signaling through IL-6/sIL-6R\u03b1 complexes.", "R": "The description of R species from the paper is: \"The multiscale model comprises three overlapping structural modules spanning spatial scales from cellular to organ levels. The first module describes events at the cellular level and consists of a reduced model of IL-6\u2013mediated signal transduction. The second module is made up of target organs relevant in Crohn\u2019s disease, and the first module (the cell signaling model) is embedded within these organs. The third and final module is a general PK model for monoclonal antibodies, including specific target binding that is linked to the first two modules to study the action of drug on the system.\"", "R_IL6": "R_IL6 species refers to the interleukin-6 (IL-6) signaling module within the multiscale systems model developed for Crohn's disease. It is a critical component of the model representing the molecular interactions and signaling dynamics associated with IL-6-mediated immune regulation. This module integrates processes such as IL-6 receptor binding, activation of the Janus kinase-signal transducer and activator of transcription (Jak-STAT) pathway, and downstream effects on biomarker expression linked to Crohn's disease pathology.", "R_IL6_gp130{gut}": "R_IL6_gp130{gut} represents the interleukin-6 signaling complex involving gp130 in the gastrointestinal tract, which is implicated in the inflammatory response observed in Crohn's disease.", "R_IL6_gp130{liver}": "R_IL6_gp130{liver} represents the liver compartment in a multiscale systems pharmacology model investigating interleukin-6 (IL-6) signaling in Crohn's disease. The model integrates intracellular signaling with the dynamics of pharmacological markers, focusing on the liver's role in the upregulation of acute-phase proteins, such as C-reactive protein (CRP), which are associated with the inflammatory processes in Crohn's disease. The liver compartment communicates with other organ compartments, allowing for the exchange of soluble components through blood serum, and is assumed to consist of a homogeneous population of cells with identical signaling dynamics.", "Reactive{gut}": "Reactive{gut} species refer to various inflammatory mediators and cytokines involved in the immune response in the gastrointestinal tract, particularly in diseases like Crohn's disease. These include interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R), C-reactive protein (CRP), and phosphorylated signal transducer and activator of transcription 3 (pSTAT3). These species are elevated in Crohn's disease and play a crucial role in driving the inflammatory processes and immune regulation within the gut environment.", "Reactive{liver}": "**Reactive{liver} species**: This species represents the liver's role in the upregulation of acute-phase proteins associated with Crohn\u2019s disease, such as C-reactive protein (CRP). It is part of the multiscale systems model that integrates IL-6 signaling dynamics with organ-level kinetics, reflecting the liver's involvement in the systemic inflammatory response characterizing the disease.", "sgp130{gut}": "The coreceptor gp130 can also exist in a soluble form (sgp130), acting as a natural inhibitor of trans-signaling by sequestering the IL-6/sIL-6R\u03b1 complex.", "sgp130{liver}": "The coreceptor gp130 can also exist in a soluble form (sgp130), acting as a natural inhibitor of trans-signaling by sequestering the IL-6/sIL-6R\u03b1 complex.", "sgp130{serum}": "The coreceptor gp130 can also exist in a soluble form (sgp130), acting as a natural inhibitor of trans-signaling by sequestering the IL-6/sIL-6R\u03b1 complex.", "sR_IL6_sgp130{gut}": "sR_IL6_sgp130{gut} represents the soluble form of the interleukin-6 receptor (sIL-6R) complexed with soluble glycoprotein 130 (sgp130) in the gastrointestinal tract. This complex acts as a natural inhibitor of IL-6 trans-signaling, sequestering the IL-6/sIL-6R complex and preventing downstream signaling events associated with inflammation and immune response in the context of Crohn's disease.", "sR_IL6_sgp130{liver}": "The description of sR_IL6_sgp130{liver} species is not directly found in the provided text. Please provide a specific section from the article if you have one in mind or confirm if there is a specific aspect related to sR_IL6_sgp130{liver} you would like to inquire about.", "sR_IL6_sgp130{serum}": "The species description for sR_IL6_sgp130{serum} is as follows: It is a soluble form of the interleukin-6 receptor component gp130 that acts as a natural inhibitor of IL-6 trans-signaling by sequestering the IL-6/sIL-6R\u03b1 complex.", "sR_IL6{gut}": "sR_IL6{gut} represents the soluble interleukin-6 receptor (sIL-6R\u03b1) found in the gastrointestinal tract. It is produced through alternative gene splicing and shedding of the transmembrane IL-6 receptor. The shedding process is thought to be accelerated by proteins like C-reactive protein (CRP). The presence of sIL-6R\u03b1 in the gut contributes to IL-6 signaling, particularly through trans-signaling mechanisms important in the context of inflammatory conditions such as Crohn\u2019s disease.", "sR_IL6{liver}": "sR_IL6{liver} is a soluble form of the interleukin-6 receptor (IL-6R\u03b1) produced in the liver, which can mediate IL-6 signaling in a trans-signaling manner. It plays a role in the inflammatory response associated with Crohn's disease by interacting with IL-6 and contributing to the regulation of immune responses, potentially influencing the survival of T-cells and the secretion of chemokines.", "sR_IL6{serum}": "sR_IL6{serum} is the soluble form of the interleukin-6 receptor found in serum, which plays a critical role in mediating IL-6 signaling through the trans-signaling pathway. It is produced by alternative gene splicing and shedding of the membrane-bound IL-6 receptor, and its levels are generally elevated in conditions such as Crohn's disease, contributing to the inflammatory response.", "sR{gut}": "sR{gut} refers to the soluble form of the IL-6 receptor (sIL-6R\u03b1) in the gastrointestinal (GI) tract, which is involved in the IL-6 signaling pathway. This receptor is produced through alternative gene splicing and shedding of the membrane-bound IL-6 receptor (IL-6R\u03b1). In Crohn's disease, the levels of sIL-6R\u03b1 are reported to be elevated, contributing to the pro-inflammatory environment in the GI tract and playing a role in the pathophysiology of the disease. The interaction between IL-6 and sIL-6R\u03b1 is of particular interest for therapeutic strategies targeting IL-6-mediated signaling.", "sR{liver}": "The liver was included for its prominent role in the upregulation of acute-phase proteins associated with Crohn\u2019s disease, such as C-reactive protein (CRP).", "sR{serum}": "sR{serum}: Serum is modeled as a separate compartment representing the circulation through which organs exchange serum-soluble molecules. All molecules in this compartment have basal production and decay terms; soluble IL-6 receptor (sIL-6R\u03b1) is produced by C-reactive protein (CRP)-mediated shedding.", "STAT3{gut}": "STAT3 is a signal transducer and activator of transcription that is phosphorylated by Janus kinase (Jak) family proteins in response to interleukin-6 (IL-6) signaling. In the context of Crohn\u2019s disease, STAT3 phosphorylation (pSTAT3) is involved in enhancing T-cell survival and resistance to apoptosis in the lamina propria, contributing to the proinflammatory environment typical of the disease. The model developed in the study specifically assesses the dynamics of pSTAT3 in relation to various therapeutic strategies targeting IL-6 signaling.", "STAT3{liver}": "STAT3{liver} is involved in the IL-6 signaling pathway, where it becomes phosphorylated (pSTAT3) in response to IL-6 signaling via the IL-6/IL-6R\u03b1 complex and gp130, leading to the transcription of various gene products associated with the inflammatory response in the liver."}